Tumor Response Equipment
-
Manufactured by Aptevo Therapeuticsbased in USA
, potentially leading to more robust anti-tumor ...
-
Manufactured by IN8Bio Inc.based in USA
-of-care to drive improved anti-tumor response. The Phase 1 repeat dose escalation clinical trial of INB-200 is being conducted at the O’Neal Comprehensive Cancer Center at the University of Alabama at ...
-
by Genmab A/Sbased in DENMARK
to elicit an anti-tumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation, using inert DuoBody IgG1 antibody ...
-
Manufactured by MedGenome Inc.based in USA
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the ...
-
Manufactured by Rubius Therapeutics, Inc.based in USA
to activate and expand NK cells. It is expected to produce a broad and potent anti-tumor T cell response, an innate immune response and have anti-tumor activity in those tumor types with known sensitivity to T cell killing, including tumor types with high mutational burden, PD-L1 expression and ...
-
Manufactured by Kaio Therapy, LLCbased in USA
Kaio Therapy's Immune Activation Heat Therapy is a novel hyperthermia system that delivers precisely controlled heat at the cellular level within a tumor. Because Kaio’s IAHT elegantly induces necrosis while activating a systemic, tumor specific response, it can also serve as a platform for other immunotherapies seeking higher ...
-
Manufactured by Brooklyn ImmunoTherapeutics (BTX)based in USA
Why human derived? Brooklyn has developed a powerful method to create complex cytokine mixtures derived from a human source. Cytokines are powerful immune factors that play an essential role in T cell signaling, activation, proliferation, and tumor-fighting responses. We know cytokines may induce beneficial reactions in cancer patients. To ...
-
Manufactured by Elicio Therapeuticsbased in USA
-cell response, including both CD4+ and CD8+ populations, that correlates with tumor biomarker responses, potentially leading to improved clinical ...
-
Manufactured by Rubius Therapeutics, Inc.based in USA
RTX-321 is an allogeneic, off-the-shelf artificial antigen presenting cell (aAPC) therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I ...
-
Manufactured by TxinnoBioscience Inc.based in SOUTH KOREA
STING-mediated type I interferon production and subsequently prevents innate immune response against tumor. It was suggested that cancer cells acquire immune evasiveness by increasing ENPP1 expression, reflecting over-expression of ENPP1 in many different cancer ...
-
Manufactured by OSE Immunotherapeuticsbased in FRANCE
closely linked to tumor activity and responsiveness to T-cell-targeted ...
-
Manufactured by Senti Biosciencesbased in USA
Natural Killer (NK) cells are essential components of the immune system, playing an important role in the body’s defensive response against tumors and infected cells. NK cells constantly patrol the body to detect and neutralize foreign cells. Senti Bio believes there are several advantages that NK cells confer in relation to other ...
-
Manufactured by BTNX Inc.based in CANADA
The Rapid Response Bladder Tumor Antigen Test Cassette is a lateral flow chromatographic immunoassay for the qualitative detection of bladder tumor antigen in human urine. It is intended to aid in the diagnosis and management of bladder cancer patients. In practice, patient urine is added to the sample well and allowed to react with a ...
-
Manufactured by Fate Therapeutics, Inc.based in USA
. Resistance to checkpoint inhibitor therapy has been linked to impaired immune cell infiltration into the tumor, impaired cytokine response, and deficiencies in antigen presentation including altered expression of major histocompatibility (MHC) class I complex. As a result, there is significant unmet need for novel therapeutic approaches to ...
-
based in FRANCE
Regulatory T cells (Tregcells) represents a cell population with strong immunosuppressive activities. In cancer patients, Treg cells can dampen protective immune responses against tumor antigens. Moreover, high infiltration by Treg cells has been associated with poor survival invarious types of cancer. Therapeutic strategiesto eliminateTreg ...
-
Manufactured by Shanghai Henlius Biotech, Incbased in CHINA
-escalation Phase 1 clinical study (HLX07FIH, NCT02648490) for the treatment of advanced solid tumours. Tumour response was observed in this study and preliminary efficacy of HLX07 was ...
-
Manufactured by Ibio, Inc.based in USA
T cells [Tregs] proliferate and suppress the immune responses to tumor cells. The Treg is a type of T cell that is important in preventing autoimmunity by keeping effector T cells [Teffs] “in-check” to prevent destruction of healthy tissues. However, around tumors, Tregs create an immunosuppressive environment and block the ...
-
Manufactured by Tonix Pharmaceuticals Holding Corp.based in USA
at low levels in splenic immune cells and is now appreciated to have intravascular roles in spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several ...
-
Manufactured by Elekta Instrument ABbased in SWEDEN
Elekta Unity is our ground-breaking MR-Linac. It brings together diagnostic quality MR imaging with a linear accelerator to deliver unprecedented visibility and precision. The system’s continuous, rich and timely insights into motion and response enable truly precise and personalized radiotherapy. Watch workflow video ...
-
Manufactured by Kymab, a Sanofi companybased in UNITED KINGDOM
Alomfilimab SAR445256 (formerly KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Alomfilimab is designed to exert anti-tumour activity through preferential depletion of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you